Immunization has shown excellent results against infectious diseases such as polio and measles, but continued success requires sustained political and financial commitment. Unfortunately, immunization as a whole remains an unfinished business as too many children are still dying of vaccine preventable diseases. As President and General Manager of Pfizer’s Vaccines and an IFPMA Vaccine CEO Steering Committee member, Ms Susan Silbermann talks about why investing in vaccines is so valuable and how the effective introduction and rollout of new vaccines can save millions of more lives.
IFPMA 2014 interview series ‘The Value of investing in immunization’
Published on: 24 April 2014